title: Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children.
abstract: B cell lymphoproliferative disorders (BLPD) are relatively frequent after genotypically non-HLA-identical BMT. We performed univariate analysis to study which BMT-related variables were associated with an increased risk of developing BLPD. Sixty-five recipients of other than genotypically HLA-identical BM grafts were included in the study. Seventy-seven recipients of genotypically HLA-identical BM grafts served as a comparison group. BLPD occurred in nine of 65 children after non-HLA-identical BMT (14%) and in none of the 77 children after HLA-identical BMT (0%). In all cases, BLPD was proven to be EBV-related. Our data suggest that the combined use of Campath 1G and anti-LFA1 was associated with an increased risk of developing BLPD, particularly children who had received a T cell-depleted BM graft, using albumen density gradient sedimentation followed by E-rosetting, and who were conditioned with Ara-C, CY and TBL. In addition, T cell numbers below 50/microliters at 1 month and below 100/microliters at 2 months after BMT, respectively, were associated with an increased risk of developing BLPD. Longitudinal determination of T cell numbers after non-HLA-identical BMT is a simple method for identifying patients at risk of developing BLPD. In addition to monitoring levels of circulating EBV-infected lymphocytes, monitoring T cell numbers may allow early intervention to prevent progression of BLPD.
authors.affiliation: Department of Paediatrics, Leiden University Hospital, The Netherlands.
authors.forename: E J
authors.initials: EJ
authors.lastname: Gerritsen
authors.forename: E D
authors.initials: ED
authors.lastname: Stam
authors.forename: J
authors.initials: J
authors.lastname: Hermans
authors.forename: H
authors.initials: H
authors.lastname: van den Berg
authors.forename: A
authors.initials: A
authors.lastname: Haraldsson
authors.forename: M J
authors.initials: MJ
authors.lastname: van Tol
authors.forename: R L
authors.initials: RL
authors.lastname: van den Bergh
authors.forename: J L
authors.initials: JL
authors.lastname: Waaijer
authors.forename: A C
authors.initials: AC
authors.lastname: Kroes
authors.forename: P M
authors.initials: PM
authors.lastname: Kluin
authors.forename: J M
authors.initials: JM
authors.lastname: Vossen
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D006566:Herpesviridae Infections / Q000150:complications*; D004854:Herpesvirus 4, Human; D006650:Histocompatibility Testing; D006801:Humans; D007223:Infant; D016393:Lymphoma, B-Cell / Q000209:etiology*; D012307:Risk Factors; D014412:Tumor Virus Infections / Q000150:complications*